{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:11:58Z","timestamp":1788387118314,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CSCO Clinical Oncology Research Foundation of Beijing","award":["Y-tongshu2021\/ms-0072"],"award-info":[{"award-number":["Y-tongshu2021\/ms-0072"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06312-9","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T03:19:34Z","timestamp":1759807174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Deficient DNA mismatch repair and Nectin-4 expression in upper tract urothelial carcinoma (UTUC)"],"prefix":"10.1007","volume":"151","author":[{"given":"Peichen","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shudong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"6312_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, Mertens LS, Meijer RP, Milowsky MI, Neuzillet Y, Panebianco V, Redlef J, Rink M, Rouanne M, Thalmann GN, S\u00e6bj\u00f8rnsen S, Veskim\u00e4e E, van der Heijden AG (2024) European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol 85:17\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.016","journal-title":"Eur Urol"},{"key":"6312_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ygyno.2009.02.004","volume":"113","author":"H Arabi","year":"2009","unstructured":"Arabi H, Guan H, Kumar S, Cote M, Bandyopadhyay S, Bryant C, Shah J, Abdul-Karim FW, Munkarah AR, Ali-Fehmi R (2009) Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecol Oncol 113:153\u2013158. https:\/\/doi.org\/10.1016\/j.ygyno.2009.02.004","journal-title":"Gynecol Oncol"},{"key":"6312_CR3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1158\/1078-0432.Ccr-18-2039","volume":"25","author":"F Audenet","year":"2019","unstructured":"Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie H, Iyer G, Bochner BH, Coleman JA, Solit DB (2019) Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. Clin Cancer Res 25:967\u2013976. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2039","journal-title":"Clin Cancer Res"},{"key":"6312_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/14656566.2022.2150966","volume":"24","author":"A Bianchi","year":"2023","unstructured":"Bianchi A, von Deimling M, Pallauf M, Yanagisawa T, Kawada T, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Majdoub M, Motlagh RS, Pradere B, Karakiewicz PI, Cerruto MA, Antonelli A, Shariat SF (2023) Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond. Expert Opin Pharmacother 24:177\u2013195. https:\/\/doi.org\/10.1080\/14656566.2022.2150966","journal-title":"Expert Opin Pharmacother"},{"key":"6312_CR5","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/s0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, Chakraborti P, Donovan JL, Elliott PA, French A, Jagdev S, Jenkins B, Keeley FX Jr., Kockelbergh R, Powles T, Wagstaff J, Wilson C, Todd R, Lewis R, Hall E (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 395:1268\u20131277. https:\/\/doi.org\/10.1016\/s0140-6736(20)30415-3","journal-title":"Lancet"},{"key":"6312_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09259-z","volume":"22","author":"ML Calandrella","year":"2022","unstructured":"Calandrella ML, Francesconi S, Caprera C, Mosillo C, Caserta C, Giannarelli D, Corsi M, Macrini S, Guida A, Ascani S, Bracarda S (2022) Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study. BMC Cancer 22:168. https:\/\/doi.org\/10.1186\/s12885-022-09259-z","journal-title":"BMC Cancer"},{"key":"6312_CR7","doi-asserted-by":"publisher","first-page":"8699","DOI":"10.1038\/sj.onc.1206964","volume":"22","author":"JW Catto","year":"2003","unstructured":"Catto JW, Azzouzi AR, Amira N, Rehman I, Feeley KM, Cross SS, Fromont G, Sibony M, Hamdy FC, Cussenot O, Meuth M (2003) Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene 22:8699\u20138706. https:\/\/doi.org\/10.1038\/sj.onc.1206964","journal-title":"Oncogene"},{"key":"6312_CR8","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.Can-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Avi\u00f1a H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Do\u00f1ate F, Morrison K, Stover DR (2016) Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 76:3003\u20133013. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-1313","journal-title":"Cancer Res"},{"key":"6312_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1158\/1078-0432.Ccr-15-1678","volume":"22","author":"JC Dudley","year":"2016","unstructured":"Dudley JC, Lin MT, Le DT, Eshleman JR (2016) Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22:813\u2013820. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1678","journal-title":"Clin Cancer Res"},{"key":"6312_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-5-23","volume":"5","author":"KM Ericson","year":"2005","unstructured":"Ericson KM, Isinger AP, Isfoss BL, Nilbert MC (2005) Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma. BMC Cancer 5:23. https:\/\/doi.org\/10.1186\/1471-2407-5-23","journal-title":"BMC Cancer"},{"key":"6312_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.acuro.2014.03.010","volume":"38","author":"A Garc\u00eda-Tello","year":"2014","unstructured":"Garc\u00eda-Tello A, Ram\u00f3n de Fata F, Andr\u00e9s G, Ropero S, L\u00f3pez JI, Angulo JC (2014) DNA repair genes and prognosis in sporadic forms of urothelial carcinoma of the upper urinary tract. Actas Urol Esp 38:600\u2013607. https:\/\/doi.org\/10.1016\/j.acuro.2014.03.010","journal-title":"Actas Urol Esp"},{"key":"6312_CR12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/ajcp\/aqaa100","volume":"154","author":"MG Gayhart","year":"2020","unstructured":"Gayhart MG, Johnson N, Paul A, Quillin JM, Hampton LJ, Idowu MO, Smith SC (2020) Universal mismatch repair protein screening in upper tract urothelial carcinoma. Am J Clin Pathol 154:792\u2013801. https:\/\/doi.org\/10.1093\/ajcp\/aqaa100","journal-title":"Am J Clin Pathol"},{"key":"6312_CR13","doi-asserted-by":"publisher","first-page":"148.e17","DOI":"10.1016\/j.urolonc.2022.12.008","volume":"41","author":"T Gerald","year":"2023","unstructured":"Gerald T, Margulis V, Meng X, Bagrodia A, Cole S, Qin Q, Call SG, Mauer E, Lotan Y, Woldu SL (2023) Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients. Urol Oncol 41:148.e17\u201348.e24. https:\/\/doi.org\/10.1016\/j.urolonc.2022.12.008","journal-title":"Urol Oncol"},{"key":"6312_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","volume":"84","author":"P Grivas","year":"2023","unstructured":"Grivas P, Park SH, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ull\u00e9n A, Loriot Y, Sridhar SS, Yamamoto Y, Petrylak DP, Sternberg CN, Gupta S, Huang B, Costa N, Laliberte RJ, di Pietro A, Valderrama BP, Powles T (2023) Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN bladder 100 phase 3 trial. Eur Urol 84:95\u2013108. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.030","journal-title":"Eur Urol"},{"key":"6312_CR15","first-page":"6796","volume":"62","author":"A Hartmann","year":"2002","unstructured":"Hartmann A, Zanardo L, Bocker-Edmonston T, Blaszyk H, Dietmaier W, Stoehr R, Cheville JC, Junker K, Wieland W, Knuechel R, Rueschoff J, Hofstaedter F, Fishel R (2002) Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res 62:6796\u20136802","journal-title":"Cancer Res"},{"key":"6312_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2022.2124691","volume":"11","author":"J Huang","year":"2022","unstructured":"Huang J, Su R, Chen Z, Jiang S, Chen M, Yuan Y, Hu H, Fu C, Huang Z, Wang Z, Zheng B, Li C, Wang Z, Bao Y, Cai M, Guo J, Wei Q, Xue W (2022) The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy. Oncoimmunology 11:2124691. https:\/\/doi.org\/10.1080\/2162402x.2022.2124691","journal-title":"Oncoimmunology"},{"key":"6312_CR17","doi-asserted-by":"publisher","first-page":"7398","DOI":"10.3390\/curroncol30080536","volume":"30","author":"G Hui","year":"2023","unstructured":"Hui G, Stefanoudakis D, Zektser Y, Isaacs DJ, Hannigan C, Pantuck AJ, Drakaki A (2023) Do cancer genetics impact treatment decision making? Immunotherapy and beyond in the management of advanced and metastatic urothelial carcinoma. Curr Oncol 30:7398\u20137411. https:\/\/doi.org\/10.3390\/curroncol30080536","journal-title":"Curr Oncol"},{"key":"6312_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jjco\/hyz140","volume":"50","author":"T Ito","year":"2020","unstructured":"Ito T, Kono K, Eguchi H, Okazaki Y, Yamamoto G, Tachikawa T, Akagi K, Okada Y, Kawakami S, Morozumi M, Tamaru JI, Ishida H (2020) Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population. Jpn J Clin Oncol 50:80\u201388. https:\/\/doi.org\/10.1093\/jjco\/hyz140","journal-title":"Jpn J Clin Oncol"},{"key":"6312_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/jclinpath-2021-207855","volume":"76","author":"F Kullmann","year":"2023","unstructured":"Kullmann F, Strissel PL, Strick R, Stoehr R, Eckstein M, Bertz S, Wullich B, Sikic D, Wach S, Taubert H, Olbert P, Heers H, Lara MF, Macias ML, Matas-Rico E, Lozano MJ, Prieto D, Hierro I, van Doeveren T, Bieche I, Masliah-Planchon J, Beaurepere R, Boormans JL, Allory Y, Herrera-Imbroda B, Hartmann A, Weyerer V (2023) Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. J Clin Pathol 76:126\u2013132. https:\/\/doi.org\/10.1136\/jclinpath-2021-207855","journal-title":"J Clin Pathol"},{"key":"6312_CR20","doi-asserted-by":"publisher","first-page":"7745","DOI":"10.7150\/thno.77281","volume":"12","author":"Y Liang","year":"2022","unstructured":"Liang Y, Tan Y, Guan B, Guo B, Xia M, Li J, Shi Y, Yu Z, Zhang Q, Liu D, Yang X, Hao J, Gong Y, Shakeel M, Zhou L, Ci W, Li X (2022) Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma. Theranostics 12:7745\u20137759. https:\/\/doi.org\/10.7150\/thno.77281","journal-title":"Theranostics"},{"key":"6312_CR21","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.Ccr-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R (2019) FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 25:3753\u20133758. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-4070","journal-title":"Clin Cancer Res"},{"key":"6312_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.eururo.2023.05.011","volume":"84","author":"JJ Meeks","year":"2023","unstructured":"Meeks JJ, Black PC, Galsky M, Grivas P, Hahn NM, Hussain SA, Milowsky MI, Steinberg GD, Svatek RS, Rosenberg JE (2023) Checkpoint inhibitors in urothelial carcinoma-future directions and biomarker selection. Eur Urol 84:473\u2013483. https:\/\/doi.org\/10.1016\/j.eururo.2023.05.011","journal-title":"Eur Urol"},{"key":"6312_CR23","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/jim-2016-000342","volume":"65","author":"A Naboush","year":"2017","unstructured":"Naboush A, Roman CA, Shapira I (2017) Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge. J Investig Med 65:754\u2013758. https:\/\/doi.org\/10.1136\/jim-2016-000342","journal-title":"J Investig Med"},{"key":"6312_CR24","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/jco.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucian\u00f2 R, Colecchia M, Giannatempo P, Mortarini R, Bianchi M, Far\u00e8 E, Monopoli F, Colombo R, Gallina A, Salonia A, Messina A, Ali SM, Madison R, Ross JS, Chung JH, Salvioni R, Mariani L, Montorsi F (2018) Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase ii study. J Clin Oncol 36:3353\u20133360. https:\/\/doi.org\/10.1200\/jco.18.01148","journal-title":"J Clin Oncol"},{"key":"6312_CR25","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.euf.2020.08.001","volume":"7","author":"A Necchi","year":"2021","unstructured":"Necchi A, Madison R, Pal SK, Ross JS, Agarwal N, Sonpavde G, Joshi M, Yin M, Miller VA, Grivas P, Chung JH, Ali SM (2021) Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma. Eur Urol Focus 7:1339\u20131346. https:\/\/doi.org\/10.1016\/j.euf.2020.08.001","journal-title":"Eur Urol Focus"},{"key":"6312_CR26","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/jco.22.02887","volume":"41","author":"PH O'Donnell","year":"2023","unstructured":"O\u2019Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE (2023) Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J Clin Oncol 41:4107\u20134117. https:\/\/doi.org\/10.1200\/jco.22.02887","journal-title":"J Clin Oncol"},{"key":"6312_CR27","doi-asserted-by":"publisher","first-page":"e910","DOI":"10.1093\/oncolo\/oyad120","volume":"28","author":"T Peak","year":"2023","unstructured":"Peak T, Spiess PE, Li R, Grivas P, Necchi A, Pavlick D, Huang RSP, Lin D, Danziger N, Jacob JM, Bratslavsky G, Ross JS (2023) Comparative genomic landscape of urothelial carcinoma of the bladder among patients of East and South Asian genomic ancestry. Oncologist 28:e910\u2013e920. https:\/\/doi.org\/10.1093\/oncolo\/oyad120","journal-title":"Oncologist"},{"key":"6312_CR28","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/s1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, B\u00f6gemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Su\u00e1rez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J (2020) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 21:1574\u20131588. https:\/\/doi.org\/10.1016\/s1470-2045(20)30541-6","journal-title":"Lancet Oncol"},{"key":"6312_CR29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, G\u00fcm\u00fc\u015f M, Mar N, Loriot Y, Fl\u00e9chon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390:875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"6312_CR30","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/jco.19.02044","volume":"38","author":"J Rosenberg","year":"2020","unstructured":"Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, Wu C, Gartner EM, Zuo P, Melhem-Bertrandt A, Petrylak DP (2020) EV-101: a phase I study of single-agent enfortumab vedotin in patients with Nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 38:1041\u20131049. https:\/\/doi.org\/10.1200\/jco.19.02044","journal-title":"J Clin Oncol"},{"key":"6312_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat M, Seisen T, Birtle AJ, Capoun O, Comp\u00e9rat EM, Dominguez-Escrig JL, G\u00fcrses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, Pradere B, van Rhijn BWG, Shariat SF, Rai BP, Soria F, Soukup V, Wood RG, Xylinas EN, Masson-Lecomte A, Gontero P (2023) European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol 84:49\u201364. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.013","journal-title":"Eur Urol"},{"key":"6312_CR32","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1016\/j.clgc.2020.03.006","volume":"18","author":"B Schneider","year":"2020","unstructured":"Schneider B, Glass \u00c4, Jagdmann S, H\u00fchns M, Claus J, Zettl H, Dr\u00e4ger DL, Maruschke M, Hakenberg OW, Erbersdobler A, Zimpfer A (2020) Loss of Mismatch-repair protein expression and microsatellite instability in upper tract urothelial carcinoma and clinicopathologic implications. Clin Genitourin Cancer 18:e563\u2013e572. https:\/\/doi.org\/10.1016\/j.clgc.2020.03.006","journal-title":"Clin Genitourin Cancer"},{"key":"6312_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/ajcp\/aqw209","volume":"147","author":"AR Sepulveda","year":"2017","unstructured":"Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA (2017) Molecular biomarkers for the evaluation of colorectal cancer. Am J Clin Pathol 147:221\u2013260. https:\/\/doi.org\/10.1093\/ajcp\/aqw209","journal-title":"Am J Clin Pathol"},{"key":"6312_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1012168","volume":"12","author":"Z Shang","year":"2022","unstructured":"Shang Z, Jin S, Wang W, Wei Y, Gu C, Yang C, Zhu Y, Zhu Y, Shen Y, Wu J, Ye D (2022) Clinicopathological characteristics and loss of mismatch repair protein expression in Chinese upper tract urothelial carcinomas. Front Oncol 12:1012168. https:\/\/doi.org\/10.3389\/fonc.2022.1012168","journal-title":"Front Oncol"},{"key":"6312_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"6312_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pathol.2020.09.004","volume":"53","author":"T Takahara","year":"2021","unstructured":"Takahara T, Murase Y, Tsuzuki T (2021) Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes. Pathology 53:56\u201366. https:\/\/doi.org\/10.1016\/j.pathol.2020.09.004","journal-title":"Pathology"},{"key":"6312_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.humpath.2023.10.003","volume":"142","author":"B Tekin","year":"2023","unstructured":"Tekin B, Cheville JC, Herrera Hernandez L, Negron V, Smith CY, Jenkins SM, Dasari S, Enninga EAL, Norgan AP, Menon S, Cubilla AL, Whaley RD, Jimenez RE, Thompson RH, Leibovich BC, Karnes RJ, Boorjian SA, Pagliaro LC, Erickson LA, Guo R, Gupta S (2023) Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma. Hum Pathol 142:42\u201350. https:\/\/doi.org\/10.1016\/j.humpath.2023.10.003","journal-title":"Hum Pathol"},{"key":"6312_CR38","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, \u00dcr\u00fcn Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD (2023) Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med 389:1778\u20131789. https:\/\/doi.org\/10.1056\/NEJMoa2309863","journal-title":"N Engl J Med"},{"key":"6312_CR39","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/1078-0432.Ccr-21-1935","volume":"30","author":"HC Wilbur","year":"2024","unstructured":"Wilbur HC, Le DT, Agarwal P (2024) Immunotherapy of MSI cancer: facts and hopes. Clin Cancer Res 30:1438\u20131447. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1935","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06312-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06312-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06312-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:00:29Z","timestamp":1762264829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06312-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6312"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06312-9","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients have been given informed consent and that the study protocol was approved by the institute\u2019s committee on human research. This study protocol was reviewed and approved by Peking University Third Hospital Medical Science Research Ethics Committee (M2023800). This study protocol was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Human research participants have provided informed consent for publication of the images in Figs.\n                      \n                      and\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"280"}}